Early diagnosis of colorectal cancer via plasma proteomic analysis of CRC and advanced adenomatous polyp

• Published in: Gastroenterology and hepatology from bed to bench 2019, Vol.12 (4), p.328-339
• Main Authors: Fayazfar, Setareh, Zali, Hakimeh, Arefi Oskouie, Afsaneh, Asadzadeh Aghdaei, Hamid, Rezaei Tavirani, Mostafa, Nazemalhosseini Mojarad, Ehsan
• Format: Article
• Language: English
• Subjects: Original
• ISSN: 2008-2258; 2008-4234
• DOI: 10.22037/ghfbb.v12i4.1723

This paper aimed to identify new candidate biomarkers in blood for early diagnosis of CRC. Colorectal cancer (CRC) is the third most widespread malignancies increasing globally. The high mortality rate associated with colorectal cancer is due to the delayed diagnosis in an advanced stage while the metastasis has occurred. For better clinical management and subsequently to reduce mortality of CRC, early detection biomarkers are in high demand. A 2D-PAGE separation of proteins was performed followed by tandem mass Spectrometry (MALDI-TOF-TOF) to discover potential plasma protein markers for CRC and AA (advanced adenomas). Furthermore, western blot method was used to confirm a part of the results in colorectal tissue samples. The significantly altered proteins including HPR, HP, ALB, KRT1, APOA1, FGB, IGJ and C4A were down-regulated in polyp relative to normal, and CRC compare to polyp surprisingly, and inversely, ORM2 was up-regulated with the fold change ≥ 2 and p-value ≤ 0.05. We also surveyed APOA1, FGB, and C4A for further confirmation of their expression changes by western blotting. All three of them showed a decreasing trend from normal toward CRC tissue samples as it mentioned before, but just changes of FGB and C4A were significant. The results demonstrated that plasma proteins can be less invasive markers for the detection of CRC. FGB and C4A can be considered as plasma potential biomarkers to early diagnosis of CRC patients and understanding the underlying procedures in tumorigenesis. Undoubtedly, the additional study must be conducted on large scale cohorts to verify the results.